Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor

Surgical Oncology

Volumn 17, Issue 2, 2008, Pages 113-128

  Markopoulos, Christos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Anastrozole; Aromatase inhibitor; Breast conserving surgery; Exemestane; Letrozole; Metastases; Neoadjuvant therapy; Predictive factors; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTILIPEMIC AGENT; AROMATASE INHIBITOR; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN RECEPTOR; EXEMESTANE; KI 67 ANTIGEN; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; UROKINASE;

ADJUVANT THERAPY; BONE PAIN; BRAIN ISCHEMIA; BREAST SURGERY; COGNITION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DOCTOR PATIENT RELATION; DRUG EFFICACY; ECHOGRAPHY; ENDOMETRIUM CANCER; FATIGUE; FRACTURE; GENE EXPRESSION; HEALTH PROMOTION; HEART PROTECTION; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYSTERECTOMY; INSOMNIA; LUNG EMBOLISM; MAMMOGRAPHY; MICROARRAY ANALYSIS; MYALGIA; ONCOGENE NEU; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; REVIEW; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME; TUMOR RESISTANCE; UTERUS CANCER; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL;

EID: 41949110999     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2007.11.006     Document Type: Review

References (119)

1. Lamerato L., Havstad S., Gandhi S., Jones D., and Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. Journal of Clinical Oncology 23 Suppl. 16 (2005) 62s Abstract 738
2. Saphner T., Tormey D.C., and Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. Journal of Clinical Oncology 14 (1996) 2738-2746
3. Mansell R., Monypenny I.J., Skene A.I., et al. Predictors of early recurrence in postmenopausal women with operable breast cancer. Breast Cancer Research and Treatment 100 Suppl. 1 (2006) S111 Abstract 2091
4. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351 (1998) 1451-1467
5. Oh S., Heflin L., Meyerowitz B.E., Desmond K.A., Rowland J.H., and Ganz P.A. Quality of life of breast cancer survivors after a recurrence: a follow-up study. Breast Cancer Research and Treatment 87 (2004) 45-57
6. Henley E. Understanding the risks of medical interventions. Family Practice Management 7 (2000) 59-60
7. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. Journal of Clinical Oncology 23 (2005) 619-629
8. Goldhirsch A., Wood W., Gelber R., et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Annals of Oncology 18 (2007) 1133-1144
9. Dixon J.M., Anderson T.J., and Miller W.R. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. European Journal of Cancer 38 (2002) 2214-2221
10. Semiglazov V. Exemestane (E) vs. tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). Journal of Clinical Oncology 23 Suppl. 16 (2005) 11S Abstract 530
11. Semiglazov V.F., Semiglazov V.V., Dashyan G.A., et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110 (2007) 244-254
12. Smith I.E., Dowsett M., Ebbs S.R., IMPACT Trialists Group, et al., Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. Journal of Clinical Oncology 23 (2005) 5108-5116
13. Cataliotti L., Buzdar A.U., Noguchi S., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 106 (2006) 2095-2103
14. Eiermann W., Paepke S., Appfelstaedt J., Letrozole Neo-Adjuvant Breast Cancer Study Group, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Annals of Oncology 12 (2001) 1527-1532
15. Dowsett M. Biological lessons from pre-surgical endocrine therapy. European Journal of Cancer 5 Suppl. (2007) 25 [Abstract 88]
16. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. Journal of Clinical Oncology 19 (2001) 3808-3816
17. Renshaw L., Murray J., Young O., Cameron D., Miller W.R., and Dixon J.M. Is there an optimal duration of neoadjuvant letrozole therapy?. Breast Cancer Research and Treatment 88 Suppl. 1 (2004) S36 [Abstract 405]
18. McArthur H.L., Olivotto I., Gelmon K.A., et al. Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. Breast Cancer Research and Treatment 94 Suppl. 1 (2005) S124 [Abstract 3001]
19. Lawrence G., Pritchard M.G., Kearins O., and Casey M. An analysis of breast cancer recurrences for screen detected and symptomatic breast cancers diagnosed in the West Midlands in 1996 and 1997. Breast Cancer Research and Treatment 94 Suppl. 1 (2005) S211 [Abstract 5019]
20. Kryj M., Maciejewski B., Withers H.R., and Taylor J.M. Incidence and kinetics of distant metastases in patients with operable breast cancer. Neoplasma 44 (1997) 3-11
21. Rugo HS. Adjuvant therapies: distant disease-free survival as a predictor of overall survival. In: Presented at primary therapy of early breast cancer 10th international conference, St. Gallen, Switzerland, March 14-17, 2007 [Abstract 120].
22. Clarke M., Collins R., Darby S., et al., Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 366 (2005) 2087-2106
23. Punglia R.S., Morrow M., Winer E.P., and Harris J.R. Local therapy and survival in breast cancer. New England Journal of Medicine 356 (2007) 2399-2405
24. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
25. Rugo HS, Kaura S, Dranitsaris G. The number needed to treat (NNT) as a measure of drug efficacy: the case of aromatase inhibitors (AIs) in postmenopausal women with early breast cancer. In: Presented at primary therapy of early breast cancer 10th international conference, St. Gallen, Switzerland, March 14-17, 2007 [Abstract 170].
26. Naylor C.D., Chen E., and Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness?. Annals of Internal Medicine 117 (1992) 916-921
27. Fisher B., Costantino J., Redmond C., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. New England Journal of Medicine 320 (1989) 479-484
28. Houghton J., and on behalf of the ATAC Trialists' Group. Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: updated data from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. Journal of Clinical Oncology 23 Suppl. 16 (2005) 24S [Abstract 582]
29. Ludwig Breast Cancer Study Group. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1 (1984) 1256-1260
30. The Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh A. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Lancet 2 (1987) 171-175
31. 'Nolvadex' Adjuvant Trial Organisation. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. British Journal of Cancer 57 (1988) 608-611
32. Rutqvist L.E., Cedermark B., Glas U., Johansson H., Nordenskjöld B., Skoog L., et al. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Research and Treatment 10 (1987) 255-266
33. Leborgne F., Leborgne J.H., Ortega B., Doldan R., and Zubizarreta E. Breast conservation treatment of early stage breast cancer: patterns of failure. International Journal of Radiation Oncology, Biology, Physics 31 (1995) 765-775
34. Stearns V., Johnson M.D., Rae J.M., et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute 95 (2003) 1758-1764
35. Jin Y., Desta Z., Stearns V., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. Journal of the National Cancer Institute 97 (2005) 30-39
36. Howell A., Cuzick J., Baum M., and ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
37. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine 353 (2005) 2747-2757 (correction N Engl J Med 2006;354:2200)
38. Jones S.E. Exemestane as adjuvant treatment of early breast cancer: Intergroup Exemestane Study/Tamoxifen Exemestane Adjuvant Multicenter trials. Clinical Breast Cancer 6 Suppl. 2 (2006) S41-S44
39. Coombes R.C., Kilburn L.S., Snowdon C.F., Intergroup Exemestane Study, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
40. Jonat W., Gnant M., Boccardo F., et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta analysis. Lancet Oncology 7 (2006) 991-996
41. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New England Journal of Medicine 349 (2003) 1793-1802
42. Mamounas E., Jeong J.-H., Wickerham L., et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Breast Cancer Research and Treatment 100 Suppl. 1 (2006) S22 [Abstract 49]
43. Jakesz R., Samonigg H., Greil R., on behalf of the ABCSG, et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). Journal of Clinical Oncology 23 16S (2005) 10s [Abstract 527]
44. Coombes R.C., Hall E., Gibson L.J., Intergroup Exemestane Study, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine 350 (2004) 1081-1092
45. Baum M., Budzar A.U., Cuzick J., and ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139 [correction Lancet 2002;360:1520]
46. Houghton J. Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T)-data reported on behalf of the ATAC ('Arimidex', tamoxifen, alone or in Combination) Trialists' group. Annals of Oncology 17 Suppl. 9 (2006) ix94 [Abstract 243PD]
47. Rasmussen B.B., Regan M.M., Lykkesfeldt A.E., et al. Central assessment of ER, PgR and HER2 in BIG 1-98 evaluating letrozole (L) compared to tamoxifen (T) as initial adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer. Journal of Clinical Oncology 25 18S (2007) 12s [Abstract 538]
48. Mauriac L., Keshaviah A., Debled M., et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Annals of Oncology 18 (2007) 859-867
49. Coates A.S., Keshaviah A., Thürlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Journal of Clinical Oncology 25 (2007) 486-492
50. Love R.R., Mazess R.B., Barden H.S., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New England Journal of Medicine 326 (1992) 852-856
51. Kristensen B., Ejlertsen B., Dalgaard P., et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. Journal of Clinical Oncology 12 (1994) 992-997
52. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncology 2006;7:633-43.
53. Braithwaite R.S., Chlebowski R.T., Lau J., George S., Hess R., and Col N.F. Meta-analysis of vascular and neoplastic events associated with tamoxifen. Journal of General Internal Medicine 18 (2003) 937-947
54. McDonald C.C., Alexander F.E., Whyte B.W., Forrest A.P., and Stewart H.J. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. British Medical Journal 311 (1995) 977-980
55. Demissie S., Silliman R.A., and Lash T.L. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. Journal of Clinical Oncology 19 (2001) 322-328
56. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 90 (1998) 1371-1388
57. Cuzick J., Wale C., and on Behalf of the ATAC Trialists' Group. A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years treatment. Breast Cancer Research and Treatment 100 Suppl. 1 (2006) S24 [Abstract 104]
58. Duffy S., and on Behalf of the ATAC Trialists' Group. Anastrozole is associated with a lower risk of endometrial abnormalities than tamoxifen: first report of the ATAC trial endometrial sub-protocol at 6 years follow-up. Breast Cancer Research and Treatment 100 Suppl. 1 (2006) S190 [Abstract 4055]
59. Monfardini S., Brunello A., and Molino A. Comorbidity and choice of adjuvant endocrine therapy in breast cancer patients (pts) older than 70 years. Journal of Clinical Oncology 24 18S (2006) 479s [Abstract 8546]
60. Fisher B., Dignam J., Bryant J., and Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. Journal of the National Cancer Institute 9 (2001) 684-690
61. Bryant J., Fisher B., and Dignam J. Duration of adjuvant tamoxifen therapy. Journal of the National Cancer Institute Monographs 30 (2001) 56-61
62. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute 97 (2005) 1262-1271
63. Crivellari D., Sun Z., Coates A.S., et al. Aromatase inhibitors (AIs) for elderly patients: efficacy, compliance and safety according to patient age in the BIG 1-98 trial. Journal of Clinical Oncology 25 18S (2007) 501s [Abstract 9033]
64. Salgado B.A., and Zivian M.T. Aromatase inhibitors: side effects reported by 612 women. Breast Cancer Research and Treatment 100 Suppl. 1 (2006) S168 [Abstract 3131]
65. Jakesz R., Jonat W., Gnant M., on behalf of the ABCSG and the GABG, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
66. Perez E.A. The balance between risks and benefits: long-term use if aromatase inhibitors. European Journal of Cancer 4 Suppl. (2006) 16-25
67. Pritchard K.I., and Abramson B.L. Cardiovascular health and aromatase inhibitors. Drugs 66 (2006) 1727-1740
68. Monnier A, Sakek N, Aladen S. Comparing AI cardiovascular safety data: trial comparators and outcomes. In: Presented at primary therapy of early breast cancer 10th international conference, St. Gallen, Switzerland, March 14-17, 2007 [Abstract 109].
69. Markopoulos C., Polychronis A., Zobolas V., et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Research and Treatment 93 (2005) 61-66
70. Sourander L., Rajala T., Räihä I., Mäkinene J., Erkkola R., and Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 352 (1998) 1965-1969 [correction Lancet 1999;353:330]
71. Medicines and Healthcare Products Regulatory Agency. Public assessment report Femara 2.5 mg tablet. January 12, 2005.
72. Wasan K.M., Goss P.E., Pritchard P.H., et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Annals of Oncology 16 (2005) 707-715
73. Markopoulos C., Chrissochou M., Antonopoulou Z., et al. Duration of tamoxifen effect on lipidemic profile of postmenopausal breast cancer patients following deprivation of treatment. Oncology 70 (2006) 301-305
74. Markopoulos C., Chrissochou M., Michailidou A., et al. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anticancer Drugs 16 (2005) 879-883
75. Thorne C. Clinical management of arthralgia and bone health in women undergoing adjuvant aromatase inhibitor therapy. Current Opinion in Oncology 19 Suppl. 1 (2007) S19-S28
76. North American Menopause Society (NAMS). Menopause guidebook: helping women make informed healthcare decisions around menopause and beyond. 6th ed. 2006; 〈www.menopause.org/edumaterials/guidebook/mgtoc.htm〉.
77. Loibl S., Schwedler K., von Minckwitz G., Strohmeier R., Mehta K.M., and Kaufmann M. Clonidine vs. venlafaxine as treatment for hot flashes in breast cancer patients: a double-blind randomized study. Journal of Clinical Oncology 23 16 (2005) 738s [Abstract 8038]
78. Bygdeman M., and Swahn M.L. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 23 (1996) 259-263
79. Mackey J., and Gelmon K. Adjuvant aromatase inhibitors in breast cancer therapy: significance of musculoskeletal complications. Current Opinion in Oncology 19 Suppl. 1 (2007) S9-S18
80. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. Journal of Clinical Oncology 21 (2003) 4042-4057
81. Chien A.J., and Goss P.E. Aromatase inhibitors and bone health in women with breast cancer. Journal of Clinical Oncology 24 (2006) 5305-5312
82. Lonning P., Geisler J., Krag L.E., et al. Vitamin D deficiency: a threat to bone health in breast cancer patients during adjuvant treatment with aromatase inhibitors. Journal of Clinical Oncology 24 18S (2006) 16s [Abstract 554]
83. Brufsky A., Dong M., Lund K., et al. Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). Breast Cancer Research and Treatment 100 Suppl. 1 (2006) S233 [Abstract 5060]
84. Brufsky A., Bundred N., Coleman R., et al. An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). Breast Cancer Research and Treatment 100 Suppl. 1 (2006) S25 [Abstract 107]
85. Burstein H.J. Aromatase inhibitor-associated arthralgia syndrome. Breast 16 (2007) 223-224
86. Presant C., Kelly C., Bosserman L., et al. Aromatase inhibitor (AI)-associated arthralgia (A) and bone pain (BP): frequency and characterization in clinical practice. Journal of Clinical Oncology 24 18S (2006) 334s [Abstract 6137]
87. Crew K.D., Capodice J., Greenlee H., et al. Effect of acupuncture on joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients. Breast Cancer Research and Treatment 100 Suppl. 1 (2006) S236 [Abstract 5071]
88. Garreau J.R., Delamelena T., Walts D., Karamlou K., and Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. American Journal of Surgery 192 (2006) 496-498
89. Dixon J.M., Renshaw L., Young O., et al. Anastrozole and letrozole an investigation and comparison of quality of life, tolerability and morbidity. Breast Cancer Research and Treatment 100 Suppl. 1 (2006) S24 [Abstract 105]
90. Stearns V., Beebe K.L., Iyengar M., and Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. Journal of American Medical Association 289 (2003) 2827-2834
91. Loprinzi C.L., Sloan J.A., Perez E.A., et al. Phase III evaluation of fluoxetine for treatment of hot flashes. Journal of Clinical Oncology 20 (2002) 1578-1583
92. Whelan T.J., and Pritchard K.I. Managing patients on endocrine therapy: focus on quality-of-life issues. Clinical Cancer Research 12 3 Part 2 (2006) 1056s-1060s
93. Loprinzi C.L., Abu-Ghazaleh S., Sloan J.A., et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. Journal of Clinical Oncology 15 (1997) 969-973
94. Jenkins V., Atkins L., and Fallowfield L. Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition?. European Journal of Cancer 43 (2007) 1342-1347
95. Schilder C.M., Eggens P.C., Boogerd W., van Dam F.S., and Schagen S.B. Journal of Clinical Oncology 25 18S (2007) 19s [Abstract 566]
96. Jenkins V., Shilling V., Fallowfield L., Howell A., and Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13 (2004) 61-66
97. Bender C.M., Sereika S.M., Ryan C.M., et al. Memory impairments with anastrozole versus tamoxifen therapy in women with early stage breast cancer. Breast Cancer Research and Treatment 94 Suppl. 1 (2005) S274 [Abstract 6074]
98. Jenkins V., Atkins L., Ambroisine L., Fleissig A., Fallowfield L., and Howell A. Preliminary results from the IBIS II (prevention) cognitive sub-protocol. Breast Cancer Research and Treatment 100 Suppl. 1 (2006) S238 [Abstract 5076]
99. Ray-Coquard I. Hospital volume specialization, guidelines and outcomes in cancer treatment: importance in quality of cancer care. European Journal of Cancer 4 (2006) 181 [Abstract 447]
100. Hebert-Croteau N., Brisson J., Latreille J., Rivard M., Abdelaziz N., and Martin G. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. Journal of Clinical Oncology 22 (2004) 3685-3693
101. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology-Version 2.2006. 12-5-05 ©2006 National Comprehensive Cancer Network, Inc.
102. Pestalozzi B.C., Luporsi-Gely E., Jost L.M., Bergh J., and ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Annals of Oncology 16 Suppl. 1 (2005) i7-i9
103. Wengström Y., Aapro M., Leto di Priolo S., Cannon H., and Georgiou V. Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study. Breast (2007) [Epub ahead of print]
104. Davidson B., Vogel V., and Wickerham L. Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy. Journal of Supportive Oncology 5 (2007) 139-143
105. Ma C.X., and Ellis M.J. Neoadjuvant endocrine therapy for locally advanced breast cancer. Seminars in Oncology 33 (2006) 650-656
106. Hinestrosa M.C., Dickersin K., Klein P., et al. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nature Reviews Cancer 7 (2007) 309-315
107. Fabian C.J., Kimler B.F., Zalles C.M., et al. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Research and Treatment (2007) [Epub ahead of print]
108. Larionov A., Miller W., White S., et al. High density micro-arrays do not accurately reflect the decrease in MKI67 in breast cancers during treatment with the aromatase inhibitors anastrozole and letrozole. Breast Cancer Research and Treatment 100 Suppl. 1 (2006) S221 [Abstract 5026]
109. Ellis M.J., Coop A., Singh B., et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Research 63 (2003) 6523-6531
110. Miller W.R., White S., Dixon J.M., Murray J., Renshaw L., and Anderson T.J. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. British Journal of Cancer 94 (2006) 1051-1056
111. Akashi-Tanaka S., Omatsu M., Shimizu C., et al. Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy. Breast (2007) [Epub ahead of print]
112. Miller W.R., Ellis M.J., Tao Y., Bhatnagar A., Evans D.B., and Sasano H. Absence of post treatment tumour expression of aromatase is associated with reduced antiproliferative effects of letrozole (but not tamoxifen) in the P024 adjuvant endocrine therapy trial. Breast Cancer Research and Treatment 100 Suppl. 1 (2006) S186 [Abstract 4045]
113. Harbeck N., Schmitt M., Paepke S., Allgayer H., and Kates R.E. Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms. Critical Reviews in Clinical Laboratory Science 44 (2007) 179-201
114. Llombart-Cussac A., Ruiz A., Lopez-Guerrero J.A., Guerrero A., Fuster-Diana C., Tena I., et al. Objective response to neoadjuvant letrozole predicts distant disease free survival in postmenopausal women with stage II-III ER/PGR-positive breast cancer. Annals of Oncology 17 Suppl. 9 (2006) ix96 [Abstract 252P]
115. Miller W.R., Renshaw L., Larionov A., Anderson T.J., White S., Hampton G., et al. Prediction of hormone response in breast cancer by microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy with letrozole. Journal of Clinical Oncology 23 16S (2005) 198s [Abstract 3025]
116. Clinical Trials.gov identifier NCT00310180. National Institutes of Health Web site. 〈www.clinicaltrials.gov/ct/show/NCT00310180?order=1〉. Accessed May 18, 2007.
117. Tuma R.S. A big trial for a new technology: TransBIG Project takes microarrays into clinical trials. Journal of the National Cancer Institute 96 (2004) 648-649
118. Rutgers EJ. Breast International Group 1 MINDACT trial: a prospective trial to validate the Amsterdam Signature. American Society of Clinical Oncology Educational Book. 43rd Annual Meeting; June 1-5, 2007; Chicago, IL. pp. 40-44.
119. Clinical Trials.gov identifier NCT00199134. National Institutes of Health Web site. 〈www.clinicaltrials.gov/ct/show/NCT00199134?order=1〉. Accessed May 18, 2007.